Sarepta pushes back Elevidys timeline; Emergent lays off 90 staffers

Sarepta delays Elevidys non-ambulatory study to Q1 2027; Emergent cuts 90 roles; Context axes CT-95; argenx sole bidder for Forte; BioVie's bezisterim hits Phase 2 goals.

Raccontata daendpoints.news